Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PTAFR | P25105 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813892 | 0.85 | NR3C1 (0.53) | NR3C1PTAFR | |
| SCHEMBL14510334 | 0.73 | HTR2A (0.38) | — | |
| SCHEMBL6825245 | 0.70 | NR3C1 (0.47) | NR3C1L3MBTL1PTAFR | |
| SCHEMBL4417984 | 0.69 | NR3C1 (0.42) | NR3C1L3MBTL1PTAFR | |
| SCHEMBL14535310 | 0.68 | CYP2D6 (0.45) | NR3C1L3MBTL1CYP3A4MAPTTHRB | |
| SCHEMBL21452433 | 0.67 | NR3C1 (0.47) | NR3C1L3MBTL1PTAFR | |
| SCHEMBL3834286 | 0.67 | PDE4A (0.54) | NR3C1PTAFRMAPT | |
| SCHEMBL1494013 | 0.65 | NR3C1 (0.64) | NR3C1PTAFR | |
| Ammonia Solution, Strong SCHEMBL265635 | 0.65 | NR3C1 (0.58) | NR3C1PTAFR | |
| SCHEMBL6996727 | 0.65 | KDM1A (0.72) | NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123491-A1 | Podophyllotoxin derivatives as igf-1r inhibitors | BIOVITRUM AB (SE) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123491-A1 | Podophyllotoxin derivatives as igf-1r inhibitors | IGF1R, IGFBP1, INSR | NR3C1 1734/4885L3MBTL1 2706/4885PTAFR 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.